Chronic Lymphocytic Leukemia
Conditions
Interventions
Experimental group:Venetoclax combined with BTK inhibitors
Sponsors
The West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Confirmed CLL (according to the 2016 World Health Organization (WHO) classification criteria for lymphoid and hematopoietic system tumors or in accordance with the 2018 International Chronic Lymphocytic Leukemia Workshop (iwCLL 2018) standards, diagnosed as CLL through histopathology and/or flow cytometry); 2. Have received BTKi (including ibrutinib, zanubrutinib and obinutinib) treatment for more than 1 year and have achieved a response (PR or better); 3. Age >= 18 years and 6 months; 5. Adequate hematological function, defined as: absolute neutrophil count (ANC) >= 1.0×10^9/L; PLT count >= 50×10^9/L; 6. Patients with basically normal liver, kidney, lung and heart functions; 7. The patient or their legal representative must provide written informed consent before undergoing any special examinations or procedures of the study.
Exclusion criteria
Exclusion criteria: 1. Comorbid with uncontrolled cardiovascular and cerebrovascular diseases, coagulation disorders, connective tissue diseases, severe infectious diseases, etc.; 2. Other concurrent medical conditions that the subjects consider will affect their participation in the study and are not under control; 3. Psychiatric patients or other patients known or suspected to be unable to fully comply with the study protocol; 4. Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Optimal MRD rate;Safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression Free Survival; | — |
Countries
China
Contacts
Public ContactKai Shen
The West China Hospital of Sichuan University
Outcome results
None listed